Although pemigatinib (Pemazyre) is currently the only FDA approved treatment for adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangements, together this work underscores the activity of selective FGFR inhibitors, highlights the importance of available next-generation FGFR inhibitors to address resistance, and identifies novel drug combinations that could enhance the impact of FGFR inhibitors, potentially providing an avenue to decrease drug toxicities associated with these treatments in patients with FGFR-fusion driven leukemias.4 The gene discussed is FGFR1; the disease is lymphoid neoplasm.